10x Genomics says Q2 2026 revenue rises 3% as Atera orders and consumables growth offset instrument slide
TXG•Q2 revenue rises 3% excluding settlement revenue
10x Genomics posted Q2 revenue of $151 million; $1.6 million came from Takara settlement-related license and royalty revenue.
Excluding non-recurring settlement revenue in both periods, revenue was $149 million, up 3% on year, driven by consumables strength.
Consumables growth offsets instrument decline; outlook lifted
Consumables revenue rose 7%; Single Cell consumables grew 3% on double-digit reaction-volume gains tied to Flex Apex adoption.
Spatial consumables increased 16% on higher Xenium utilization; instrument revenue fell 47% on fewer units sold.
Full-year revenue outlook lifted to $610 million-$630 million; Atera orders exceeded the 40-unit shipment plan, with most shipments expected in Q4.
